当前位置: X-MOL 学术Ann. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer
Annals of Oncology ( IF 56.7 ) Pub Date : 2017-08-03 , DOI: 10.1093/annonc/mdx275
J.A. Ajani , M. Abramov , I. Bondarenko , Y. Shparyk , V. Gorbunova , A. Hontsa , N. Otchenash , M. Alsina , S. Lazarev , J. Feliu , A. Elme , V. Esko , K. Abdalla , U. Verma , F. Benedetti , T. Aoyama , H. Mizuguchi , L. Makris , G. Rosati

The effect of histology-based treatment regimen on diffuse gastric adenocarcinoma has not been evaluated in clinical trials. This international phase III trial evaluated the efficacy and safety of S-1 (a contemporary oral fluoropyrimidine)/cisplatin versus 5-fluorouracil (5-FU)/cisplatin in chemotherapy-naïve patients with diffuse-type adenocarcinoma involving the gastroesophageal junction or stomach.

中文翻译:

一项III期临床试验,比较未经治疗的弥漫性胃癌患者口服S-1 /顺铂和静脉内5-氟尿嘧啶/顺铂

在临床试验中尚未评估基于组织学的治疗方案对弥漫性胃腺癌的影响。这项国际III期临床试验评估了S-1(当代口服氟嘧啶)/顺铂与5-氟尿嘧啶(5-FU)/顺铂在未进行过化疗的弥漫型腺癌(涉及胃食管交界处或胃部)的患者中的疗效和安全性。
更新日期:2017-09-18
down
wechat
bug